Please login to the form below
voxilaprevir
This page shows the latest voxilaprevir news and features for those working in and with pharma, biotech and healthcare.
Gilead wins European approval for triple hep C combination Vosevi
The treatment brings together sofosbuvir, velpatasvir and voxilaprevir. Gilead Sciences has chalked up a big win with its hepatitis C treatment Vosevi (sofosbuvir/velpatasvir/voxilaprevir) as it becomes the first and
Latest news
-
Gilead gets OK for three-in-one hep C therapy in US
The approval is believed to be the first for voxilaprevir anywhere in the world. ... Gilead has also filed for the sofosbuvir, velpatasvir and voxilaprevir therapy in the EU, winning an accelerated review from the EMA in January.
-
Samsung Bioepis wins CHMP nod for second Humira biosimilar
virus (infection) - AbbVie's Maviret (glecaprevir/pibrentasvir) and Gilead's Vosevi (sofosbuvir/velpatasvir/voxilaprevir).
-
Two new hepatitis C therapies fast-tracked in Europe
EU. Gilead's application is for a three drug combination of NS5B polymerase inhibitor sofosbuvir, NS5A inhibitor velpatasvir and pan-genotypic protease inhibitor voxilaprevir – given over 12 weeks – that could achieve
-
Gilead files hepatitis C salvage regimen in US
Seeks FDA approval for combination of Epclusa and voxilaprevir. The new generation of directly-acting antiviral (DAAs) have transformed the treatment of hepatitis C virus (HCV) infections - but not all patients ... inhibitor called voxilaprevir.
-
Gilead’s hepatitis C sales start to slide – the question is how quickly?
well as a triplet therapy based on sofosbuvir, velpatasvir and voxilaprevir that is in four late-stage trials.
Gilead gets OK for three-in-one hep C therapy in US
Samsung Bioepis wins CHMP nod for second Humira biosimilar
Two new hepatitis C therapies fast-tracked in Europe
Gilead’s hepatitis C sales start to slide – the question is how quickly?
More from news
Approximately 1 fully matching, plus 5 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Account Director, Medical & Brand Communications, London/ SE...
-
Highly competitive salary
- Home Working Medical Copy Writer & Senior Medical Copy Write...
-
Highly Competitive Salary, Bonus &Benefits
- Medical Writers (All levels) Editorial / Scientific Leads & ...
-
Highly Competitive Remuneration packages
- Senior Account Director, Medical & Brand Communications, Lon...
-
Highly competitive salary
- Freelance Scientific Director, Medical Communications, London/ S...
-
Highly competitive salary
- Medical Writer, Women’s health, Medical Communications agency, h...
-
Highly competitive salary
- Senior Account Management Trainer, Medical Communications, Londo...
-
Highly competitive salary
- Editorial Director - UK, , EUROPE, REMOTE.
-
Highly Competitive Salary, Bonus &Benefits
- AstraZeneca’s Imfinzi provides sustained survival benefit for lung cancer patients
- One dose of AZ’s COVID-19 vaccine ‘highly effective’ against severe disease from variants
- EU “still interested” in Valneva COVID vaccine despite UK snub
- FDA approves Seagen/Genmab’s antibody-drug conjugate Tivdak for women with advanced cervical cancer
- First oral antiviral drug for COVID-19 reviewed by Health Canada
- Gilead’s Veklury (remdesivir) cuts risk of severe COVID-19 by 87%
- COVID-19 Pfizer/BioNTech booster approved by FDA and CDC
- AstraZeneca invests in RNA tech platform
- Market shaping demands behaviour change
- Healthcare Access and Payment Reform in the US
- Advancing Drug Discovery with Structured and Intelligent Data
- Fishawack Health appoints Elizabeth Landon in the newly created Chief People Officer role
- David Hunt launches independent agency The Considered
- Live Webinar: Making Actionable Health Information More Accessible Through Point-of-Care Testing
- WHO to test three more potential COVID-19 treatments
- EU “still interested” in Valneva COVID vaccine despite UK snub
- FDA green lights study of phage-based drug for resistant infections
- First oral antiviral drug for COVID-19 reviewed by Health Canada
PMHub
Create Health
A healthcare marketing agency that shares your passion for making things better. Our clients with solve real health problems every...
Latest intelligence
- Robust Review: COVID19 Assessment
- See how our client utilized Rapid Payer Response (RPR) to stay informed and gain continuous insights during the recent global pandemic (COVID19)...
- All change – how untangling human behaviour can encourage better health
- Driving better patient outcomes through clear, achievable practical steps that are underpinned by transparent evidence...
- Health literacy in the time of COVID-19
- In a time when much of the media’s focus is on the ongoing COVID-19 pandemic and the differences in vaccination rates between various regions, countries, and socioeconomic groups, improving health...
